z-logo
open-access-imgOpen Access
Use of the chromosomal class A beta-lactamase of Mycobacterium fortuitum D316 to study potentially poor substrates and inhibitory beta-lactam compounds
Author(s) -
Moreno Galleni,
Nicola Franceschini,
Birgit Quinting,
Lanfranco Fattorini,
Graziella Orefici,
A Oratore,
J.-M. Frère,
Gianfranco Amicosante
Publication year - 1994
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.38.7.1608
Subject(s) - mycobacterium fortuitum , cefoxitin , dicloxacillin , cloxacillin , microbiology and biotechnology , beta lactamase inhibitors , nafcillin , ceftazidime , chemistry , enzyme , beta lactamase , moxalactam , antibiotics , mycobacterium , biology , staphylococcus aureus , biochemistry , bacteria , penicillin , cephalosporin , escherichia coli , genetics , gene , pseudomonas aeruginosa
Sixteen different compounds usually considered beta-lactamase stable or representing potential beta-lactam inhibitors and inactivators were tested against the beta-lactamase produced by Mycobacterium fortuitum. The compounds exhibiting the most interesting properties were BRL42715, which was by far the best inactivator, and CGP31608 and ceftazidime, which were not recognized by the enzyme. These compounds thus exhibited adequate properties for fighting mycobacterial infections. Although cloxacillin, dicloxacillin, cefoxitin, and CP65207-2 exhibited poor inhibitory efficiency against the enzyme, they were also rather poor substrates and might be considered potential antimycobacterial agents. By contrast, CGP31523A and ceftamet were good substrates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom